STOCK TITAN
  1. Home
  2. News
  3. DCTH

Delcath Systems Inc - DCTH STOCK NEWS

Welcome to our dedicated news page for Delcath Systems (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Systems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Delcath Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Delcath Systems's position in the market.

News
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023
Rhea-AI Summary
Delcath Systems, Inc. will present at the Roth MKM Healthcare Opportunities Conference in New York on October 12. A webcast and replay of the presentation will be available. One-on-one meetings with management are also scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences
-
News
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. granted equity awards to new hires, issuing a total of 86,000 shares of common stock. The awards were granted outside of the Company's Omnibus 2020 Equity Incentive Plan. Each employee received options with an exercise price equal to the closing price of Delcath common stock on the grant date. One-third of the options will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments over the following twenty-four months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
News
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
Rhea-AI Summary
Delcath Systems, Inc. announces study comparing liver directed therapies in patients with metastatic uveal melanoma, showing significantly longer overall survival for patients treated with Chemosat vs. SIRT (516 and 301 days, respectively; p=0.006).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
News
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
Rhea-AI Summary
Delcath Systems to present at H.C Wainwright Global Investor Conference on September 13 at 11:00 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
-
News
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™
Rhea-AI Summary
Delcath Systems, Inc. raised $35 million through the exercise of Tranche A warrants, following FDA approval of HEPZATO KIT. Tranche B warrants could generate an additional $25 million. The financing triggers an extension of the interest-only period for an existing loan agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
fda approval
-
News
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
Rhea-AI Summary
FDA approves HEPZATO KIT as liver-directed therapy for metastatic uveal melanoma, Delcath to hold Business Update Call on August 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
81.73%
Tags
fda approval
News
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update
Rhea-AI Summary
Delcath Systems, Inc. reported business highlights and financial results for Q2 2023. The company is awaiting FDA review of the HEPZATO KIT NDA resubmission. Delcath received stockholder approval for potential stock issuance and generated $25 million from a private placement. They also hired a new Chief Medical Officer, Senior Vice President of Finance, and Director of Sales and Strategy. Total revenue for Q2 2023 was $0.5 million, compared to $0.8 million in the prior year. R&D expenses decreased to $3.6 million, while selling, general, and administrative expenses increased to $4.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.54%
Tags
earnings
-
News
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week
Rhea-AI Summary
Delcath Systems, Inc. plans to report its 2Q23 earnings and issue its Form 10-Q the week of August 7, 2023. The company expects the FDA to review and take action on its HEPZATO™ KIT's new drug application by the August 14, 2023 Prescription Drug User Fee Act (PDUFA) date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences earnings
-
News
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
News
Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.72%
Tags
management
Stock DCTH logo
Delcath Systems Inc

Nasdaq:DCTH

DCTH Rankings

#4023 Ranked by Market Cap
#1117 Ranked by Stock Gains
N/A Ranked by Dividends

DCTH Stock Data

125.92M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular